Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408546 · ClinicalTrials.gov registry record · Phase 2
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
A Phase 2 study, sponsored by Translational Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT05408546 is a Phase 2 study that is active but no longer recruiting, run by Translational Sciences. The registered enrollment target is 64 participants.
The verdict
NCT05408546, a Phase 2 study, is active but no longer recruiting, sponsored by Translational Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
Phase II trial of TS23
Interventions
- DRUG Placebo
- DRUG TS23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-05-24 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05408546
The ClinicalTrials.gov registry entry for NCT05408546 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Sciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05408546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05408546 about?
NCT05408546 is a clinical study titled "Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial". Phase II trial of TS23
What is the current status of trial NCT05408546?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-05-24. Estimated completion is 2026-11.
What interventions are being tested in trial NCT05408546?
The interventions under investigation include: Placebo (DRUG), TS23 (DRUG).
Who is sponsoring clinical trial NCT05408546?
This trial is sponsored by Translational Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.